486 filings
Page 5 of 25
CORRESP
ery76 nfv2q9ha7m
17 Mar 23
Correspondence with SEC
12:00am
F-1/A
axcmy84 3j
13 Mar 23
Registration statement (foreign) (amended)
9:18am
CORRESP
on51m4yhxtv
13 Mar 23
Correspondence with SEC
12:00am
CORRESP
lh3tru36neoksday5u0
13 Mar 23
Correspondence with SEC
12:00am
FWP
dvpjt
9 Mar 23
Free writing prospectus
4:31pm
6-K
zf54fof4iir51t 416fp
9 Mar 23
Current Report
4:30pm
FWP
ba3jqyc7ixg5ul abl
8 Mar 23
Free writing prospectus
10:10am
F-1/A
sdzpvg6
7 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
r49j03e
1 Mar 23
Registration statement (foreign) (amended)
1:02pm
F-1/A
cbw601lto 3t
28 Feb 23
Registration statement (foreign) (amended)
4:12pm
CORRESP
r6g8g2ky q5444kr5
28 Feb 23
Correspondence with SEC
12:00am
UPLOAD
6azfud 2bd
24 Feb 23
Letter from SEC
12:00am
6-K
h7gbn
17 Feb 23
Report of Foreign Private Issuer
4:30pm
F-1
j9emitpmsm0 unl1ypw1
16 Feb 23
Registration statement (foreign)
10:17am
6-K
qfg uywxxed8gm
27 Jan 23
Report of Foreign Private Issuer
8:50am
6-K
1b2 f3pt4q6
24 Jan 23
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
9:00am
SC 13D/A
0eooa130oyx1bl9lp1
18 Jan 23
Altamira Therapeutics / Meyer Thomas ownership change
4:30pm
424B4
fij3eabg 71pfzjin9
28 Dec 22
Prospectus supplement with pricing info
9:23am
EFFECT
2cx 35qigje
28 Dec 22
Notice of effectiveness
12:15am
UPLOAD
9fow1p pg8cjjz
22 Dec 22
Letter from SEC
12:00am